However, in our study, we did not see any changes in the PC-3 cell proliferation following treatment with HS-5 CCM after GPC-1 inhibition, suggesting that GPC-1 plays a selective role in the paracrine activation of prostate cancer cells in the bone microenvironment. The gene discussed is GPC1; the disease is prostate carcinoma.